PULSE the living trend engine
↓ Cooling Health 🔮 PULSE predicts: fades by tomorrow

In October 2024, a team of Chinese researchers at Peking University reported that a 25-year-old woman who had lived with Type 1 diabetes since childhood stopped needing insulin injections within 75 days of receiving an experimental stem cell transplant ge

A Chinese stem‑cell transplant reportedly freed a young Type 1 diabetic from insulin in just 75 days.

5sources
5articles
3velocity
-80%since first seen
2h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

In October 2024 a team at Peking University reported that a 25‑year‑old woman with lifelong Type 1 diabetes stopped needing insulin injections within 75 days after receiving an experimental stem‑cell transplant. Coverage highlights the case as a sign of potential progress.

Rockdale Citizen and KGUN 9 note that a clinical trial is expanding, while Diabetes In Control discusses whether stem‑cell therapy could change care for the disease. The Spokesman‑Review features reader responses, and Space Daily repeats the original October 2024 report.

Future reporting will focus on whether additional participants achieve similar outcomes, how regulators respond, and what next‑phase trial data emerge, according to the outlets tracking the story.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.

Quick answers

What outcome was reported for the patient in the Peking University study?

The patient reportedly stopped needing insulin injections within 75 days of the stem‑cell transplant.

Which media outlets are covering the potential of stem‑cell therapy for Type 1 diabetes?

Rockdale Citizen, KGUN 9, Diabetes In Control, The Spokesman‑Review and Space Daily are all publishing related coverage.

What is the next step mentioned in the coverage regarding the therapy?

Reports indicate that a clinical trial is expanding to include more participants.

Coverage (5)

Topics

Related trends